Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group

Caminati, Marco; Fassio, Angelo; Alberici, Federico; Baldini, Chiara; Bello, Federica; Cameli, Paolo; Conticini, Edoardo; Cottin, Vincent; Crimi, Claudia; Dagna, Lorenzo; Delvino, Paolo; Deroux, Alban; Duran, Emine; Espigol‐frigole, Georgina; Karadag, Omer; Maule, Matteo; Moiseev, Sergey; Monti, Sara; Moroni, Luca; Padoan, Roberto; Pugnet, Gregory; Taille, Camille; Toniati, Paola; Vaglio, Augusto; Emmi, Giacomo

doi:10.1111/all.15934

Anti-T2 monoclonal antibodies (mAbs) for severe-eosinophilc asthma have been recently investigated for EGPA.1 Few cases of severe asthma patients developing EGPA while on omalizumab,2 benralizumab3 or dupilumab4 have been published. We aimed to describe EGPA onset during anti-T2 mAbs treatment for severe asthma in a multinational cohort.

Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group / Caminati, Marco; Fassio, Angelo; Alberici, Federico; Baldini, Chiara; Bello, Federica; Cameli, Paolo; Conticini, Edoardo; Cottin, Vincent; Crimi, Claudia; Dagna, Lorenzo; Delvino, Paolo; Deroux, Alban; Duran, Emine; Espigol‐Frigole, Georgina; Karadag, Omer; Maule, Matteo; Moiseev, Sergey; Monti, Sara; Moroni, Luca; Padoan, Roberto; Pugnet, Gregory; Taille, Camille; Toniati, Paola; Vaglio, Augusto; Emmi, Giacomo. - In: ALLERGY. - ISSN 0105-4538. - STAMPA. - 79:(2024), pp. 516-519. [10.1111/all.15934]